Lycia has priced its initial public offering at $318 million, positioning the company to advance a pipeline built around protein degradation for allergic and autoimmune indications. The funds from the IPO support multiple programs described as protein-degrading medicines. The company’s lead development focus includes allergic conditions as well as Graves’ disease, according to the offering summary. The financing provides runway for early clinical progress and potential combination strategies. The IPO reinforces investor interest in degradation modalities beyond oncology-only use cases, as companies aim to broaden the addressable market for proteolysis and related mechanisms.